Use of Rifaximin in Patients With Functional Dyspepsia: A Randomized Controlled Trial

Trial Profile

Use of Rifaximin in Patients With Functional Dyspepsia: A Randomized Controlled Trial

Completed
Phase of Trial: Phase II/III

Latest Information Update: 23 Jan 2017

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Bacterial infections; Non-ulcer dyspepsia
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jan 2017 Primary endpoint has been met. (Adequate relief of global dyspeptic symptoms at week 8.), as per an article published in the Alimentary Pharmacology and Therapeutics.
    • 23 Jan 2017 Primary endpoint has not been met. (Adequate relief of global dyspeptic symptoms at week 4), as per an article published in the Alimentary Pharmacology and Therapeutics.
    • 23 Jan 2017 Primary endpoint has not been met. (Global symptom improvement), as per an article published in the Alimentary Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top